symptoms over time would be associated with comparatively worse outcomes in black patients than in white patients.
Methods
The design and results of the HF-ACTION study have been previously reported (clinicaltrials.gov, NCT00047437). [14] [15] [16] HF-ACTION was a trial of aerobic exercise training (36 supervised sessions followed by home-based training for the duration of follow-up) versus usual care in 2331 patients with a left ventricular ejection fraction ≤35% and New York Heart Association class II to IV symptoms despite optimal HF therapy for at least 6 weeks. We previously reported that compared with usual care, exercise training was associated with reduced depressive symptoms 17 and improved survival after covariate adjustment. 15 Race was documented by self-report using National Institutes of Health racial categories (ie, white, black, American Indian/Alaska Native, Asian, and Native Hawaiian/Pacific Islander). The baseline characteristics and outcomes by race as well as the association between race and exercise training in HF-ACTION have been previously published. 6 In the present analysis, we examined the relationship between depressive symptoms and clinical outcomes in blacks versus whites enrolled in HF-ACTION. The protocol was approved by the institutional review boards/ethics committees for each of the sites and the coordinating center. All patients voluntarily provided written informed consent with randomization between April 2003 and February 2007. The primary medical end point was allcause mortality or hospitalization. An independent Clinical Events Committee, blinded to treatment assignment, adjudicated deaths and cardiovascular hospitalizations until the first HF hospitalization. Biomarkers including NT-pro brain natriuretic peptide (BNP) were obtained and processed as previously described. 18 Median follow-up was 2.5 years.
Depressive symptoms were assessed using the Beck Depression Inventory-II (BDI-II). 19 The BDI-II is a 21-item, self-report measure of depressive symptoms, with each item using a 0-to-3 response scale (range, 0-63). Each item asks about a particular symptom of depression, as outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. 20 The BDI-II has been widely studied in patients with cardiovascular disease (CVD) and has excellent psychometric properties, including a test-retest reliability coefficient of 0.93. The BDI-II provides an assessment of the severity of symptoms of depression that is equivalent across sex, race, and ethnicity. 21 A score of ≥14 is considered to reflect clinically significant depressive symptoms. 19 
Statistical Methods
For descriptive purposes, patients were grouped by self-reported race and baseline BDI-II score (<14 versus ≥14). Baseline characteristics were described with continuous variables summarized with the median and 25th and 75th percentiles and categorical variables presented as percentages (frequency). The primary analysis used Cox proportional hazards models to compare black and white patients on the association between BDI-II score and time to all-cause mortality/hospitalization. All models included adjustment for a set of predictors that was developed for the full data set and has been used consistently in the post hoc HF-ACTION analyses. 6, 22 These adjustment variables included sex, age, smoking, blood urea nitrogen, left ventricular ejection fraction, New York Heart Association class, hypertension, diabetes mellitus, 6-minute walk distance, peak VO 2 by Weber class, Kansas City Cardiomyopathy Questionnaire score at baseline, region (United States versus Canada), β-blocker dose, mitral valve regurgitation class, and ventricular conduction category. We also included variables representing the use of any antidepressant and treatment group assignment. In the present analyses, we included these variables in multivariable models regardless of statistical significance. We modeled baseline BDI-II and BDI-II change scores as continuous variables using a restricted cubic spline function 23 to capture possible nonlinearity. Race differences in the association of events with baseline BDI-II and 3-month change in BDI-II were tested using product interaction terms. Sensitivity analyses comparing single median imputation with multiple imputation for missing data on covariates in the full model produced essentially identical parameter estimates and SEs for the variables under primary consideration. We therefore report estimates generated from the simple imputation approach.
We also conducted a series of secondary analyses. We explored the possible confounding role of worsening HF on clinical outcomes by including natriuretic peptide values in the survival models. As in the primary models, we tested for differences in association between the events and BNP and change in BNP via interaction terms, using splines to capture nonlinearity. BNP data at baseline and 3 months were available in 865 participants, thus the results of these analyses are exploratory. BNP data were transformed using the natural logarithm. One substantially outlying value in BNP change was trimmed to the next highest value. We also examined the association between baseline BDI-II and BDI-II change at 3 months and 3 secondary end points: HF-related deaths and hospitalizations, CVD-related deaths and hospitalizations, and all-cause death. Finally, we compared baseline BDI-II scores and antidepressant use in white and black patients in unadjusted analyses using Pearson's χ 2 test. A logistic regression model predicting baseline antidepressant prescription was generated and used to assess the relationship between race and antidepressant use while considering the role of potential confounding variables and moderators.
A P value of <0.05 (2-tailed) was considered statistically significant for all analyses. All analyses were performed using SAS (Cary, NC) system version 9.2 and the rms package in R (http://cran.us.rproject.org). HF-ACTION was funded by the National Heart, Lung, and Blood Institute, but no extramural funding was used to support the current analysis. The authors are solely responsible for the design and conduct of this study, all analyses, and the drafting and editing of the article.
Results
Of the 2167 patients enrolled in HF-ACTION with available BDI-II scores, 747 (34%) were black and 1420 (66%) were white. The Table compares patients with BDI-II scores <14 to those with scores ≥14 on background variables for each race. The black sample comprised 40% women, whereas 22% of the white sample were women. The median BDI-II at baseline in the black subset was 8 (interquartile range, 5-16) with 31% having a score ≥14. For whites, the median BDI-II score was also 8 (interquartile range, 4-14) with 27% having a score ≥14. There were 33 black patients and 44 white patients with a baseline BDI-II score of 0 (ie, reported an absence of any depressive symptoms). The median age for blacks was 55 years (interquartile range, 47-64 years) compared with 62 years (interquartile range, 54-70 years) for whites. Black patients tended to have nonischemic HF pathogenesis (68%) compared with whites (39%). The median ejection fraction was 25% for both blacks and whites. Patients with higher BDI-II scores tended to be younger, to have worse baseline functional status (eg, higher New York Heart Association class), and worse quality of life (eg, lower Kansas City Cardiomyopathy Questionnaire).
Five hundred twenty-one black patients (70%) and 922 (65%) whites died or were hospitalized during a followup of ≤4 years. Figure 1 presents the Kaplan-Meier event curves for all-cause mortality/hospitalization based on baseline BDI-II for each race. Patients with lower baseline BDI-II had the best event-free survival compared with those with scores above the conventional clinical cut point score of 14. Elevated depression symptoms were associated with worse outcomes, especially among blacks (see Figures I and II in the Data Supplement). In the Cox model, the race by BDI-II interaction was statistically significant (P=0.003), supporting a differential association between baseline BDI-II score and outcomes in black versus white patients (see Tables I and II in the Data Supplement for full regression model results). For blacks, the hazard ratio comparing a patient with a BDI-II score of 15 to one with a score of 5 (the 75th and 25th percentile of the BDI-II, respectively) was 1.44 (95% confidence interval [CI], 1.24-1.68). This association was nonlinear in blacks, with the strongest increase in risk occurring between scores of 0 and 14 (hazard ratio [HR], 2.13; 95% CI, 1.55-2.91; reference, score of 0; Figure 2A ).
Examining the association between change in BDI-II from baseline to 3 months and outcomes, the race by BDI-II change interaction was not statistically significant (P=0.36) suggesting that the strength of association could not be distinguished between blacks and whites. The association between change in BDI-II and mortality or hospitalization was again nonlinear (P=0.01). Compared with no change in the BDI-II, an increase of 10 points in blacks was associated with an increase in mortality or hospitalization (HR, 1.33; 95% CI, 1.12-1.57), whereas a decrease of 10 points was not significantly associated with outcomes (HR, 0.99; 95% CI, 0.86-1.15).
Within the subset of 865 participants with baseline and 3-month BNP data, there were 601 all-cause deaths or hospitalizations. We observed no race interaction with BNP at baseline (P=0.72) or for the change in BNP from baseline to 3 months (P=0.28) on outcomes. Both baseline BNP and change in BNP were associated with the primary outcome of mortality or hospitalization. Comparing the 75th percentile to the 25th percentile, baseline BNP was associated with a HR of 1.45 (95% CI, 1.26-1.68), and for the change in BNP the HR was 1.05 (95% CI, 1.02-1.08). With the inclusion of BNP in the outcomes model, the race by baseline BDI-II interaction remained significant (P=0.003), with a pattern almost identical for blacks and whites as observed in the primary analysis.
We observed similar associations between the BDI-II at baseline and the secondary end points of HF-related deaths and hospitalizations and CVD-related deaths and hospitalizations with BDI-II by race interactions (Ps<0.001). For allcause death, however, the BDI-II by race interaction was not significant (P=0.34; see Table III in the Data Supplement). Figure 2B presents the adjusted association between baseline BDI-II and 2-year survival probability in black and white patients.
In patients with a baseline BDI-II score ≥14, more white patients were prescribed antidepressants compared with blacks (42% versus 22%; P<0.0001). After multivariable adjustment for the same set of covariates described in the primary time to event analyses, including baseline BDI-II, blacks were less likely than whites to be prescribed an antidepressant (adjusted odds ratio, 0.28; 95% CI, 0.21-0.38).
Discussion
These data support our hypothesis that elevated depressive symptoms are associated with worse clinical outcomes, especially among blacks with HF with reduced ejection fraction. In blacks, the strongest increase in mortality/hospitalization with baseline BDI-II scores occurred in scores between 0 and 14, which falls below the commonly used threshold of clinical significance. In addition, patients with BDI-II scores >14 had more adverse events including death and hospitalizations compared to non-depressed patients, even after adjusting for medical prognostic factors, including measures of disease severity. These findings confirm the importance of clinical depression as a prognostic factor, especially in blacks. Moreover, worsening depressive symptoms were associated with worse outcomes for both whites and blacks. An increase in BDI-II score from baseline to 3 months was associated with increased mortality/hospitalization, whereas a decrease was not related to outcomes. An analysis adjusting for the change in natriuretic peptide levels over time suggests that it was not worsening HF alone that led to the association between worsening depressive symptoms and poor outcomes. These data suggest the importance of attention to even modest baseline symptoms of depression and worsening of symptoms over time in blacks.
Approximately one third of black patients in HF-ACTION reported clinically significant depressive symptoms (BDI-II scores ≥14) at the time of study entry, and an additional 7% had scores <14 but were on antidepressant medication. Taken together, these observations suggest that ≈40% of the sample could be considered as having clinically significant depressive symptoms, which is consistent with similar HF cohorts. 11 Thus, there is a high prevalence of elevated depressive symptoms in blacks with HF as well as in whites. Furthermore, we noted that even among patients with clinically significant depressive symptoms (ie, BDI-II ≥14), only 22% of blacks were prescribed an antidepressant. These findings are in comparison with 42% use of antidepressants in white patients with BDI-II scores ≥14. Black patients were 72% less likely to be prescribed antidepressants after multivariable adjustment including baseline BDI-II scores. It has been noted that depression is often under-recognized and undertreated, especially among blacks. For instance, blacks with coronary artery disease were 57% less likely to be prescribed an antidepressant compared with white patients. 24 It is important for clinicians to be aware that depression may be under-recognized and undertreated in blacks with CVDs, including HF.
The optimal strategy to treat depressive symptoms in HF patients has not been delineated. Studies to date examining the benefits of antidepressant medication in patients with CVD have been mixed. The randomized Sertraline Against Depression and Heart Disease in Chronic Heart Failure (SADHART-CHF) study showed no benefit for antidepressant medication in patients with HF compared with placebo for cardiovascular outcomes. 25 However, other studies of antidepressant therapy in patients with CVD have suggested that the subgroup of patients with severe depression may benefit from antidepressant therapy. 26 Furthermore, patients with HF with depressive symptoms have lower health-related quality of life, poorer self-care, and increased healthcare service use. [27] [28] [29] Remission from depression improves cardiovascular outcomes. 28 Thus, pharmacological therapy may represent one component of comprehensive management for depression and black patients are undertreated. Other treatment approaches, including exercise training, have been noted to reduce depressive symptoms, 30 improve cardiovascular biomarkers, 31 and may be just as effective as antidepressant medications. 32 Higher baseline BDI-II scores were associated with increased all-cause mortality or hospitalization in blacks. Specifically, compared with a patient with a score of 5 on the BDI-II, an black patient with a BDI-II score of 15 had a >44% increase in hazard for the composite of mortality and hospitalization. By way of comparison with other studies, a prior analysis demonstrated that each 1-point increase in baseline BDI-I was associated with a HR of 1.1 (95% CI, 1.06-1.14) for cardiovascular hospitalization or mortality. 13 Rescaling our hazard ratios to a difference of 1 point on the BDI-II to facilitate comparison, we found an association of greater magnitude among blacks (HR, 1.07; 95% CI, 1.04-1.11) than for whites (HR, 1.01; 95% CI, 0.98-1.03).
Notably, the depressive symptom burden captured by BDI-II scores between 0 and about 15, which largely fall below the typical threshold of clinical significance (ie, BDI ≥14), was associated with worse outcomes in black patients. The nonlinear nature of the association in blacks also suggested that the event risk tended not to increase as scores rose above ≈15, but there was relatively sparse representation of scores in this more severe symptom range. Conclusions on the association in this upper range would require confirmation in additional samples. These data add, however, to the evidence suggesting that elevated depressive symptoms not meeting diagnostic criteria for major depressive disorder are associated with worse outcomes in patients with CVD. 33 Thus, the risk for worse outcomes associated with even modest elevations in baseline BDI-II score is even greater in black patients than in white patients.
The specific reasons for the observation of a differential association between baseline depressive symptoms and the composite outcomes in black patients with HF are unknown. Given the lack of a race interaction for the all-cause mortality end point, these data suggest that the differential association may be largely attributable to increased rehospitalization risk associated with depressive symptoms in black patients. Depressive symptoms may lead to comparatively increased rehospitalization in blacks because of an increased comorbidity burden and socioeconomic stressors. 34 For instance, an increased prevalence of diabetes mellitus in blacks compared with whites could complicate medical regimens. Depressive symptoms may exacerbate issues such as polypharmacy particularly on a background of other health disparities.
The current analysis revealed that both black and white patients whose depressive symptoms worsened during the initial 3 months were at particularly increased risk of death or hospitalization. These findings are consistent with those from a previous study of 147 HF patients, in which an increase in BDI-I scores >1 year was independently associated with increased death or cardiovascular hospitalization. 13 In the overall HF-ACTION cohort, an increase in BDI-II score of 10 points was associated with a 21% increase in the rate of mortality or hospitalization. 17 In the present analysis, there was insufficient evidence to suggest a differential association between change in BDI-II score and outcomes in blacks compared with white patients. Nonetheless, the magnitude of the association between BDI-II increase and worse outcomes was larger in black patients. An increase of 10 points on BDI-II was associated with a 33% increase in risk for all-cause mortality or hospitalization in blacks. Thus, worsening depression seems to identify a black subgroup who may be particularly vulnerable to increased event rates. Efforts to prevent worsening of depression through pharmacological and lifestyle changes including exercise may be especially important in blacks. 17 Finally, we used a subsample of our data to explore whether worsening HF, as captured by changes in BNP, might explain the association between depressive symptoms and clinical events. Both BNP at study entry and change in BNP at 3 months were positively associated with event probability, with no evidence of a race difference in this association. Importantly, the adjustment for the 2 BNP variables did not alter the association between BDI-II and events or change in BDI-II and events. Thus, to the extent that BNP is capturing the severity and progression of HF, HF per se does not seem to explain the relationship between depressive symptoms and clinical prognosis.
Limitations
This was a retrospective analysis from a clinical trial of exercise training. The study population had strict inclusion and exclusion criteria, such that these findings may not apply to those with different baseline characteristics. The cohort was substantially younger, with higher baseline HF medication use than the general HF community, and the treatment group participated in exercise training such that these results may not be generalizable to other populations. Despite covariate adjustment, other measured and unmeasured factors may have influenced these findings. In addition, some of our adjustment covariates may in fact reflect causal mechanisms, or mediators, by which depressive symptoms alter the rate of events. Statistical adjustment for causal mediators may result in an underestimate of the association between a risk factor and outcome. The present design precludes us from addressing this possibility. We used BDI-II to assess depressive symptoms, which has been well validated in patients with HF, but should not be used to diagnose clinical depression. Whether worsening depression is a cause or consequence of accelerated HF progression requires further study.
Conclusions
In black patients with HF, higher baseline BDI-II score and worsening BDI-II score for 3 months are associated with increased mortality and hospitalization. Elevated baseline BDI-II scores were associated with significantly worse outcomes in blacks versus whites. These data suggest the importance of attention to even modest baseline symptoms of depression and worsening of symptoms over time in blacks. Further studies are needed to investigate the optimal treatment approaches for depression in black patients with HF.
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